Polymorphisms in PDE4D are Associated with a Risk of COPD in Non-Emphysematous Koreans

References

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11):e442.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance — United States, 1971–2000. MMWR Surveill Summ 2002; 51(6):1–16.
   Google Scholar
• Ingebrigtsen T, Thomsen SF, Vestbo J, van der Sluis S, Kyvik KO, Silverman EK, Svartengren M, Backer V. Genetic influences on Chronic Obstructive Pulmonary Disease — a twin study. Respir Med 2010; 104(12):1890–1895.
   PubMed Web of Science ®Google Scholar
• Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis 1982; 125(4):409–415.
   PubMed Web of Science ®Google Scholar
• Lewitter FI, Tager IB, McGue M, Tishler PV, Speizer FE. Genetic and environmental determinants of level of pulmonary function. Am J Epidemiol 1984; 120(4):518–530.
   PubMed Web of Science ®Google Scholar
• Gillum RF. Chronic obstructive pulmonary disease in blacks and whites: pulmonary function norms and risk factors. J Natl Med Assoc 1991; 83(5):393–401.
   PubMed Web of Science ®Google Scholar
• Homma S, Sakamoto T, Hegab AE, Saitoh W, Nomura A, Ishii Y, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K. Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med 2006; 18(5):933–939.
   PubMed Web of Science ®Google Scholar
• Beavo JA, Brunton LL. Cyclic nucleotide research — still expanding after half a century. Nat Rev Mol Cell Biol 2002; 3(9):710–718.
   PubMed Web of Science ®Google Scholar
• Berndt A, Leme AS, Shapiro SD. Emerging genetics of COPD. EMBO Mol Med 2012; 4(11):1144–1155.
   PubMed Web of Science ®Google Scholar
• Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, Wilk JB, Willis-Owen SA, Klanderman B, Lasky-Su J, Lazarus R, Murphy AJ, Soto-Quiros ME, Avila L, Beaty T, Mathias RA, Ruczinski I, Barnes KC, Celedon JC, Cookson WO, Gauderman WJ, Gilliland FD, Hakonarson H, Lange C, Moffatt MF, O’Connor GT, Raby BA, Silverman EK, Weiss ST. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009; 84(5):581–593.
   PubMed Web of Science ®Google Scholar
• Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995; 75(4):725–748.
   PubMed Web of Science ®Google Scholar
• Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998; 157(2):351–370.
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006; 147 Suppl 1:S252–257.
   PubMed Web of Science ®Google Scholar
• Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004; 287(2):L332–343.
   PubMed Web of Science ®Google Scholar
• Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(12):1498–1505.
   PubMed Web of Science ®Google Scholar
• Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009; 5(3):e1000421.
   PubMed Web of Science ®Google Scholar
• Wilk JB, Walter RE, Laramie JM, Gottlieb DJ, O’Connor GT. Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet 2007; 8 Suppl 1:S8.
   PubMedGoogle Scholar
• Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, Lange C, Won S, Murphy JR, Beaty TH, Regan EA, Make BJ, Hokanson JE, Crapo JD, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Pillai SG, Silverman EK. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010; 42(3):200–202.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Yoo KY, Shin HR, Chang SH, Choi BY, Hong YC, Kim DH, Kang D, Cho NH, Shin C, Jin YW. Genomic epidemiology cohorts in Korea: present and the future. Asian Pac J Cancer Prev. 2005; 6(3):238–243.
   PubMedGoogle Scholar
• Affymetrix (II). BRLMM–P: a genotype calling method for the SNP 5.0 array. Technical Report. Affymetrix White Paper. 2006. Affymetrix, Inc., Santa Clara, CA, USA (http://media.affymetrix.com/support/technical/whitepapers/brlmmp_whitepaper.pdf).
   Google Scholar
• Hu HJ, Jin EH, Yim SH, Yang SY, Jung SH, Shin SH, Kim WU, Shim SC, Kim TG, Chung YJ. Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis. Exp Mol Med 2011; 43(11):613–621.
   Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364(9435):709–721.
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182(5):598–604.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374(9691):685–694.
   PubMed Web of Science ®Google Scholar
• Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533(1–3):110–117.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691):695–703.
   PubMed Web of Science ®Google Scholar